

Main achievements 2019-2022

2022 Annual Memory

Administration Council

December, 2022

Strategic Priorities defined at the end of 2019 (Strategic Plan 2020-2025)

1. Improve **curiosity driven science**, increasing its impact on health problems & solutions. Four scientific priority axes.
2. Redefine the **technological platform strategy**
3. Education: **scientific and technical career**
4. Develop a **sustainable economic model**
5. Improve **governance** and institutional functioning
6. IP Montevideo in the context of the **national and international network of academic/scientific institutions**



7. COVID 19 – Strategic Activities Defined

- 3 main task groups were created (19th march 2020) by staff willing to collaborate:
- ❖ **GT-1: Molecular Diagnosis by RT-PCR**: group led by **Dr. Moratorio** (“Experimental evolution of viruses” G4 group leader) and **Dra. Moreno** from the **School of Science, UdelaR** (Total RT-PCR tests performed: 177.037).
 - ❖ **GT-2: Dynamic nature of viral genome evolution**: led by **Dr. Iraola** (“Microbial Genomics G4 Lab” leader) and an **Inter-Institutional Group**
 - ❖ **GT-3: Immune response analysis and direct and indirect diagnoses tools**: led by our Academic Director **Prof. Dr. Otto Pritsch** (Prof. Immunobiology, School of Medicine, UDELAR)



Ministerio
de Salud Pública

FOCEM
FONDO PARA LA CONVERGENCIA
ESTRUCTURAL DEL MERCOSUR



MINISTÈRE
DE L'EUROPE ET DES
AFFAIRES ÉTRANGÈRES

FSPI

Fonds de solidarité pour les projets
innovants, les sociétés civiles, la
francophonie et le développement
humain

Main Achievements (2019-2022)

1. **Reinforce fundamental research and increase its impact on “one health” problems.**
 - *Curiosity Driven Science: G4 program + duplicate the institute “per capita” funding + scientific and technical international-fellowship program (fundraising campaign).*
2. **Redefine the technological strategy**
 - *Support the scientific priorities of the Institute = collaboration strategy + new technology acquired*
3. **Education: Scientist and Technical career**
 - *Academic leveling and salary improvement with a gender perspective program*
 - *Associate Researcher Program: 20 new stable in 5 years, important staff position for scientists!*
4. **Develop a sustainable economic model :**
 - *Public Funds: consolidate (e.g. adjusted by inflation) the government’s fund + increase our own resources by doing open innovation (SARS-CoV-2 test and Epidemiological Surveillance).*
 - *Develop a Knowledge Valorization Strategy favoring association with private sector: LAB+ Venture Builder*
5. **Improve governance and institutional functioning**
 - *Develop a healthy, creative & collaborative work environment: Human Capital Management + Performance Management System*

2. New technology acquired (2022): ~ USD 1.1 M



Chromium X Series

A new era of single cell analysis



Attune™ NxT Flow Cytometer



Seahorse XFe Pro Analyzer



4D-Nucleofector®



**Orbitrap Exploris™
240 Mass Spectrometer**



Biacore T200




Ventilated Racks & Cages

Main Strategic Achievements (2019-2022)


1. **Reinforce fundamental research and increase its impact on “one health” problems.**
 - *Curiosity Driven Science: G4 program + duplicate the institute “per capita” funding + scientific and technical international-fellowship program (donation campaign).*
2. **Redefine the technological strategy**
 - *Support the scientific priorities of the Institute = collaboration strategy + new technology acquired*
3. **Education: Scientist and Technical career**
 - *Academic leveling and salary improvement with a gender perspective program*
 - *Associate Researcher Program: 20 new stable in 5 years, important staff position for scientists!*
4. **Develop a sustainable economic model :**
 - *Public Funds: consolidate (e.g. adjusted by inflation) the government’s fund + increase our own resources by doing open innovation (SARS-CoV-2 test and Epidemiological Surveillance).*
 - *Develop a Knowledge Valorization Strategy favoring association with private sector: LAB+ Venture Builder*
5. **Improve governance and institutional functioning**
 - *Develop a healthy, creative & collaborative work environment: Human Capital Management + Performance Management System*

- ✓ *Analysis of the gender gaps and biases in Human Resources*
 - ***Previous Gender Diagnostics** used as input to planning and redesign of salary matrix with gender perspective → **Academic Leveling and Salary Improvement with Gender Perspective Program**;*
 - ***Sexual and labor prevention and harassment protocol***
 - *The **program** had a stronger impact on women, who showed more depressed salary situation;*
 - *The average salary increased was **13% for women vs 3% for men**.*

Distribution by sex of the total number of people who improved their working conditions (stability, salary)



Distribution by sex of the people who won a position in the Associate Researcher Program (2021 - 2022)



Main Strategic Achievements (2019-2022)

1. **Reinforce fundamental research and increase its impact on “one health” problems.**
 - *Curiosity Driven Science: G4 program + duplicate the institute “per capita” funding + scientific and technical international-fellowship program (donation campaign).*
2. **Redefine the technological strategy**
 - *Support the scientific priorities of the Institute = collaboration strategy + new technology acquired*
3. **Education: Scientist and Technical career**
 - *Academic leveling and salary improvement with a gender perspective program*
 - *Associate Researcher Program: 20 new stable in 5 years, important staff position for scientists!*
4. **Develop a sustainable economic model :**
 - *Public Funds: consolidate (e.g. adjusted by inflation) the government’s fund + increase our own resources by doing open innovation (SARS-CoV-2 test and Epidemiological Surveillance).*
 - *Develop a Knowledge Valorization Strategy favoring association with private sector: LAB+ Venture Builder*
5. **Improve governance and institutional functioning**
 - *Develop a healthy, creative & collaborative work environment: Human Capital Management + Performance Management System*

4. Development of a sustainable economic model

1. *Consolidate our national public budget*

- Adjusted by inflation
- **Inter-institutional agreements:** Ministry of Human Public Health, INIA, BSE, others

2. *Government vs. our “own” resources relation:*

- 100/0 → 70/30 → 55/45 → 30/70

3. *Valorization: should come after disruptive discoveries made through hypothesis-driven science.*

- We are developing a **professional strategy** throughout the entire valorization process, creating a fund (in association with the private sector) to support the valorization of our knowledge: PoC → protocompanies → startups...
- Boost our **valorization strategy** to improve our social outreach and **increase our non-conventional funding to better support curiosity driven science: Technological Transfer and Valorization Unit + International Consultant**

1. **G4 Program** – BSE/IP Montevideo/**Private Donation** (~ USD 1 M/4 years)
2. **Epidemiological surveillance** of SARS-CoV-2 and Aedes aegypti transmitted diseases: MSP (~ USD 0.5 M/2 years) + FSPI (~ USD 0.4 M/2 years)
3. **Animal Health - UMPI:**
 - National Association of several institutions for the Eradication of “Cochliomyia hominivorax” (Screwworm; ~ USD 2 M/3 years)
 - Leucosis Bovine Diagnostic Kit (Uruguay, Argentina, Brazil)
 - Animal Health Grants + Zoonotic Diseases Grants (~ USD 1 M/2 years)
4. **New Startups:**
 1. Strategic Alliance IP Montevideo/CITES, Argentina; signed in 2017;
 2. In process to select disruptive projects through the 1st LAB+ international



Ministerio
de Salud Pública






- **Created:** Dec 2016 (USD ~ 650 k)
- **Starting Date:** Jun 2017
- **Main Indication:** Obesity, Metabolic Syndrome and type 2 Diabetes
- **Lead Candidate:** Jun 2019
- **IP Portfolio:** 4 Int. patents covering 3 programs
- **Round A:** Dec 2019 (~ USD 2.7 M) → Preclinical program → Dec 2021 (~ USD 3 M) FIH - in Australia: A Phase 1, Randomized, Double-blind, Placebo-controlled, First in Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple doses of MVD1 in healthy adult volunteers
- [Clinical trial](#)



- **Created:** Nov 2019 (~ USD 650 k) + NIH (~ USD 500 k)
- **Starting Date:** Jan 2021
- **Main Goal:** Modulation of inflammasome to improve response to immunotherapy
- **IP Portfolio:** 2 Int. patents


Budget composition & evolution –

Budget Composition - 2019



■ SUBSIDY MEF ■ SERVICES ■ GRANTS ■ FOCEM ■ G4

Budget Composition - 2022




■ SUBSIDY MEF ■ SERVICES ■ GRANTS ■ FOCEM ■ G4


Main Strategic Achievements (2019-2022)

1. **Reinforce fundamental research and increase its impact on “one health” problems.**
 - *Curiosity Driven Science: G4 program + duplicate the institute “per capita” funding + scientific and technical international-fellowship program (donation campaign).*
2. **Redefine the technological strategy**
 - *Support the scientific priorities of the Institute = collaboration strategy + new technology acquired*
3. **Education: Scientist and Technical career**
 - *Academic leveling and salary improvement with a gender perspective program*
 - *Associate Researcher Program: 20 new stable in 5 years, important staff position for scientists!*
4. **Develop a sustainable economic model :**
 - *Public Funds: consolidate (e.g. adjusted by inflation) the government’s fund + increase our own resources by doing open innovation (SARS-CoV-2 test and Epidemiological Surveillance).*
 - *Develop a Knowledge Valorization Strategy favoring association with private sector: LAB+ Venture Builder*
5. **Improve governance and institutional functioning**
 - *Develop a healthy, creative & collaborative work environment: Human Capital Management + Performance Management System*

Institute Organization



Staff evolution –



8. Fundraising campaign: Human Resources Training



Best Master Thesis French Embassy in Uruguay



Best PhD Thesis Rubio Santoro-García Varela



Dr. Paulina Luisi Fellowship For Women in Science

8. “Amigos del IPMontevideo” fundraising campaign

CiVE

La construcción del Centro de Innovación en Vigilancia Epidemiológica (CiVE) del Institut Pasteur de Montevideo fue posible gracias a la donación de las siguiente personas e instituciones:

- Embajada Francia y amigos: Carlos Abboud, Max Patissier, Saceem, L'Oréal Uruguay
- Embajada del Reino Unido en Uruguay
- John Christian Schandy
- Roberto Palermo Grupo Banca... XXX
- Cámara de Especialidades Farmacéuticas y Afines (CEFA)
- Embajada de Estados Unidos en Uruguay

El CiVE fue creado el 23 de junio 2020. La inauguración del edificio se realizó el 23 de junio de 2021.

CiVE

Responsables:

- Gonzalo Moratorio, PhD.
- Gregorio Iraola, PhD.
- Pilar Moreno, PhD.



Fonds de solidarité pour les projets innovants, les sociétés civiles, la francophonie et le développement humain

[Video inauguration CiVE](#)

• **Donations:**

- **G4 labs + Scientific Room + CiVE + best thesis (~ USD 700 k 2019 - 2021)**
- **International-fellowship program: USD 140.000 (~ USD 140 k 2019 - 2021)**

8. “Amigos del IPMontevideo” fundraising campaign




8. Social Outreach: Communication Unit



EL LIBRO DE
Juegos
DE LOS PEQUEÑOS
amigos PASTEUR




Institut Pasteur
de Montevideo





¡Muchas gracias!